Ketamine: Quo vadis?

Charles B. Nemeroff

doi:10.1176/appi.ajp.2018.18010014

Ketamine: Quo vadis?

Charles B. Nemeroff

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Editorial › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	297-299
Number of pages	3
Journal	American Journal of Psychiatry
Volume	175
Issue number	4
DOIs	https://doi.org/10.1176/appi.ajp.2018.18010014
State	Published - Apr 1 2018

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1176/appi.ajp.2018.18010014

Cite this

@article{08844461986a4085ae41f036e38c5de8,

title = "Ketamine: Quo vadis?",

author = "Nemeroff, {Charles B.}",

note = "Funding Information: From the Departments of Psychiatry and Behavioral Sciences and Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami. Address correspondence to Dr. Nemeroff (cnemeroff@med.miami.edu). Dr. Nemeroff has received research support from NIH and the Stanley Medical Research Institute; he has served as a consultant for Bracket (Clintara), Fortress Biotech, Intra-Cellular Therapies, Janssen Research and Development, Magstim, Navitor Pharmaceuticals, Sunovion Pharmaceuticals, Taisho Pharmaceutical, Takeda, TC MSO, and Xhale; he has served on scientific advisory boards for the American Foundation for Suicide Prevention, the Anxiety and Depression Association of America, Bracket (Clintara), the Brain and Behavior Research Foundation, the Laureate Institute for Brain Research, Skyland Trail, and Xhale; he is a stockholder in AbbVie, Antares, BI Gen Holdings, Celgene, OPKO Health, Seattle Genetics, and Xhale; he serves on the board of directors for the American Foundation for Suicide Prevention, the Anxiety and Depression Association of America, and Gratitude America; he has received income or equity of $10,000 or more from American Psychiatric Publishing, Bracket (Clintara), Magstim, CME Outfitters, and Intra-Cellular Therapies; and he holds a patent on a method and devices for transdermal delivery of lithium (patent 6,375,990B1) and a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (patent 7,148,027B2). Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships. Accepted January 2018.",

year = "2018",

month = apr,

day = "1",

doi = "10.1176/appi.ajp.2018.18010014",

language = "English (US)",

volume = "175",

pages = "297--299",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

publisher = "American Psychiatric Association",

number = "4",

}

TY - JOUR

T1 - Ketamine

T2 - Quo vadis?

AU - Nemeroff, Charles B.

N1 - Funding Information: From the Departments of Psychiatry and Behavioral Sciences and Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami. Address correspondence to Dr. Nemeroff (cnemeroff@med.miami.edu). Dr. Nemeroff has received research support from NIH and the Stanley Medical Research Institute; he has served as a consultant for Bracket (Clintara), Fortress Biotech, Intra-Cellular Therapies, Janssen Research and Development, Magstim, Navitor Pharmaceuticals, Sunovion Pharmaceuticals, Taisho Pharmaceutical, Takeda, TC MSO, and Xhale; he has served on scientific advisory boards for the American Foundation for Suicide Prevention, the Anxiety and Depression Association of America, Bracket (Clintara), the Brain and Behavior Research Foundation, the Laureate Institute for Brain Research, Skyland Trail, and Xhale; he is a stockholder in AbbVie, Antares, BI Gen Holdings, Celgene, OPKO Health, Seattle Genetics, and Xhale; he serves on the board of directors for the American Foundation for Suicide Prevention, the Anxiety and Depression Association of America, and Gratitude America; he has received income or equity of $10,000 or more from American Psychiatric Publishing, Bracket (Clintara), Magstim, CME Outfitters, and Intra-Cellular Therapies; and he holds a patent on a method and devices for transdermal delivery of lithium (patent 6,375,990B1) and a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (patent 7,148,027B2). Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships. Accepted January 2018.

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85044819607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044819607&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2018.18010014

DO - 10.1176/appi.ajp.2018.18010014

M3 - Editorial

C2 - 29606064

AN - SCOPUS:85044819607

VL - 175

SP - 297

EP - 299

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -